Mind Medicine (NASDAQ: MNMD) stock is posting big gains in Tuesday's trading. The biotech company's share price was up 8.7% ...

Inc. (NASDAQ:MNMD – Get Free Report) shares were down 8.5% on Friday following insider selling activity. The company traded ...

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)的首席医疗官Dan Karlin最近出售了公司6,643股普通股。该公司是一家市值5.02亿美元的生物科技公司，其股票在过去一年中上涨超过100%。根据 InvestingPro 的数据，分析师对MNMD保持看好态度，多项关键指标显示公司财务状况良好。这次出售是在2024年12月26日执行的，属于根据规则10b5- ...

Mind Medicine (MindMed) MNMD is developing its lead pipeline candidate, MM120, an orally disintegrating tablet (ODT) and a ...

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)的首席法务官Mark ...

Geode Capital Management LLC boosted its holdings in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Free Report) by 10.8% during ...

Lysergic acid diethylamide is under clinical development by Mind Medicine MindMed and currently in Phase I for Pain.

Mind Medicine (MindMed) MNMD is developing its lead pipeline candidate, MM120, an orally disintegrating tablet (ODT) and a pharmaceutically optimized form of lysergide D-tartrate (LSD), for the ...

Robert Barrow, the Chief Executive Officer of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), a $502 million market cap company that has delivered an impressive 108% return... Mark Sullivan ...